Sugi Predict

Sugi Predict / Targets / HSD11B2

HSD11B2

11-beta-hydroxysteroid dehydrogenase type 2 · P80365 · HSD11B2 on Sugi Atlas →

15,668 patent compounds predicted against HSD11B2, 10,068 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL235085 SCHEMBL235085 0.62 14/20
SCHEMBL232974 SCHEMBL232974 0.55 13/20
SCHEMBL234291 SCHEMBL234291 0.42 13/20
SCHEMBL328841 SCHEMBL328841 1.00 12/20
SCHEMBL419250 SCHEMBL419250 0.81 12/20
SCHEMBL419669 SCHEMBL419669 0.81 12/20
SCHEMBL421178 SCHEMBL421178 0.81 12/20
SCHEMBL421248 SCHEMBL421248 0.81 12/20
SCHEMBL417134 SCHEMBL417134 0.72 12/20
SCHEMBL235226 SCHEMBL235226 0.68 12/20
SCHEMBL232634 SCHEMBL232634 0.63 12/20
SCHEMBL230433 SCHEMBL230433 0.63 12/20
SCHEMBL230984 SCHEMBL230984 0.60 12/20
SCHEMBL231777 SCHEMBL231777 0.60 12/20
SCHEMBL232716 SCHEMBL232716 0.59 12/20
SCHEMBL233553 SCHEMBL233553 0.59 12/20
SCHEMBL231798 SCHEMBL231798 0.51 12/20
Glycyrrhizin Glycyrrhizin (SCHEMBL17684) 1.00 11/20
Acetoxolone Acetoxolone (SCHEMBL135617) 1.00 11/20
Acetoxolone Acetoxolone (SCHEMBL420036) 1.00 11/20

Clinical trials — most relevant to HSD11B2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment PHASE4RECRUITING
The Role of Mineralocorticoid Receptors in Vascular Function PHASE2/PHASE3COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia PHASE1/PHASE2COMPLETED
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old PHASE2ACTIVE_NOT_RECRUITING
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia PHASE2COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
Linear Growth of Children With Congenital Adrenal Hyperplasia nanUNKNOWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas nanUNKNOWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Natural History of Apparent Mineralocorticoid Excess Syndrome nanCOMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Final Height in Patients With CAH nanUNKNOWN
Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia nanCOMPLETED
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Novel Biomarker for Development of T2D nanCOMPLETED
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Adrenal Function in GHD Children nanCOMPLETED
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency. nanUNKNOWN
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
CXCR4 Targeted PET Imaging in the Diagnosis and Identification of Primary Aldosteronism nanUNKNOWN
Hydrocortisone Modified-release in Adults: Real-world Monitoring of Longitudinal Outcomes in coNgenital Adrenal hYperplasia nanNOT_YET_RECRUITING
Fertility And Sexual Function In CAH: CALLIOPE nanRECRUITING
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a HSD11B2 binder may also engage these)

ProteinNameSimilarity
P51976 — 1.000 P51976 →
O77667 — 0.999 O77667 →
P50233 — 0.998 P50233 →
P51661 — 0.995 P51661 →
P50168 — 0.988 P50168 →
O43542 — 0.981 O43542 →
P52785 — 0.980 P52785 →
P51658 — 0.977 P51658 →
Q8BYG9 — 0.977 Q8BYG9 →
Q6UX07 — 0.976 Q6UX07 →
Q5T3U5 — 0.976 Q5T3U5 →
Q5SS80 — 0.975 Q5SS80 →
P51840 — 0.975 P51840 →
A6H751 — 0.974 A6H751 →
Q1WNP0 — 0.974 Q1WNP0 →
Q643R3 — 0.974 Q643R3 →
A0A0U1RPR8 — 0.973 A0A0U1RPR8 →
A7YY46 — 0.973 A7YY46 →
P0C0K6 — 0.972 P0C0K6 →
P51839 — 0.972 P51839 →
A0A061IR73 — 0.972 A0A061IR73 →
P55203 — 0.972 P55203 →
Q17QU7 — 0.972 Q17QU7 →
Q7TNJ2 — 0.972 Q7TNJ2 →
Q149M9 — 0.971 Q149M9 →
P0DPE1 — 0.971 P0DPE1 →
Q9HBH5 — 0.971 Q9HBH5 →
Q9H2F3 — 0.971 Q9H2F3 →
Q17QW3 — 0.971 Q17QW3 →
MUS81 Structure-specific endonuclease subunit MUS81 0.971 landscape →